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Background: Gastric cancer is a leading causes of cancer-related deaths ,but the underlying molecular mechanisms
of its progression are largely unknown. Differentiated embryonic chondrocyte-expressed gene 1 (DEC1), is an
important transcription factor involved in the progression of tumors and has recently been identified to be strongly
inducible by hypoxia. Little is known about the contribution of DEC1 to the intracellular hypoxia and proliferation
signaling events in gastric cancer.
Methods: Immunohistochemistry was used to detect the expression of DEC1, hypoxia-inducible factor 1(HIF-1α)
and Ki67 in 173 human gastric cancer samples and adjacent non-tumor tissues samples. The relationship between
DEC1, HIF-1α and Ki67 was evaluated.
Results: DEC1 protein was persistently expressed in the nucleus and cytoplasm of gastric cancer tissue. The protein
expression of DEC1 and HIF-1α in tumour tissues was 83.8% and 54.3%, respectively, and was significantly higher
than that in adjacent normal tissues (83.8% vs 23.7%, P <0.001; 54.3% vs 12.7%, P< 0.001). The expression of DEC1
and HIF-1α was associated with poor histological differentiation. (P < 0. 01). Furthermore, DEC1 level was positively
correlated with HIF-1α (P < 0. 01, r=0.290) and Ki67 expression (P < 0. 01, r=0.249).
Conclusion: The upregulation of DEC1 may play an important role in hypoxia regulation and cell proliferation in
gastric cancer. The relevant molecular mechanism requires further investigation.
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Human differentiated embryonic chondrocyte-expressed
gene 1 (DEC1) (also known as Stra13/Bhlhb2/Sharp2) is a
basic helix-loop-helix (bHLH) transcription factor. Al-
though little is known about its function in human physio-
logical and pathological processes, recent studies have
shown that DEC1 is a hypoxia-induced gene involved in
cell differentiation, proliferation, and apoptosis [1,2].
Miyazaki K et al. [3] identified the hypoxia response
elements in the DEC1 promoter and found that the
DEC1 gene is a direct target of hypoxia-inducible factor
1 (HIF-1). DEC1 may be a hypoxia-regulated gene, so its
expression in human tumors may be a direct marker of
tumor hypoxia. The association of the clinical value of
DEC1 expression and HIF-1α, the endogenous marker
of hypoxia, has not been reported for gastric cancer.
The studies with cultured cell lines have revealed that
DEC1 expression is associated with hypoxia and HIF-1α
protein expression, and blockage of the HIF-1α protein
led to reduced DEC1 expression [4].
The clinical progression of gastric cancer is rapid and is
reflected by various proliferation markers. The role of DEC1
in cell proliferation is inconsistent. DEC1 inhibits apoptosis
in human embryonic kidney 293 cells [5,6] and induces
apoptosis in mouse fibroblast NIH3T3 cells [7]. In addition,
DEC1 has pro-apoptotic properties in human breast cancer
cells [8].The intracellular signaling events related to the role
of DEC1 in gastric cancer have not been well established.
In this study, we used immunohistochemistry to
evaluate the expression status and clinicopathological
features of DEC1 and HIF-1α in 173 human gastric
cancer samples and its adjacent non-tumor tissues by
immunohistochemistry. The associations between DEC1
and HIF-1α, and proliferation marker Ki67 were analyzed.
Materials and methods
Patients and samples
Surgically resected gastric cancer specimens were collected
from 173 patients (117 males) at Jinan Central Hospital
Affiliated to Shandong University, China, January 2011 to
June 2012. The mean age of the patients was 62 years
(range 30–88 years). Among the 173 tumor samples,
53 were well or moderately differentiated and 120 were
poorly differentiated. The formalin-fixed, paraffin-embedded
samples were retrospectively and randomly selected from
the files of the Department of Pathology after the protocol
was approved by the local research ethics committee. All
the samples were evaluated for diagnosis by 2 experienced
pathologists for diagnosis. None of the patients had
received chemotherapy or radiation therapy preoperatively.
Immunohistochemistry
The tissues were fixed in 10% neutral buffered formalin
for 12 h and were routinely processed. The paraffin wax-embedded tissue blocks were cut into 4-μm-thick
sections. The formalin-fixed, paraffin-embedded sections
were heated at 60°C for 60 min and placed into xylene
for deparaffinization and graded ethanol for rehydration,
then washed in phosphate-buffered saline (PBS). The
antigen retrieval involved the use of a prewarmed pres-
sure cooker with a solution of antigen retrieval citrate
buffer (pH 6.8) for 3 min. Following de-pressurization,
cold water was poured into the cooker for 10 min, then
sections were rinsed well in warm water. The sections
were incubated in 3% H2O2 in methanol for 10 min,
then washed 3 times with PBS and incubated with the
primary antibodies rabbit polyclonal anti-DEC1 (1:50,
Genetex, CA, USA), mouse monoclonal anti-HIF-1α
(1:50, Santa Cruz Biotechnology, CA, USA), or rabbit
monoclonal anti-Ki67 (1:50, Cell Signaling Technology,
MA, USA) overnight in a moist chamber at 4°C. Following
a final wash, the sections were incubated with secondary
antibody (KIT-5010, Max Vision, Maixin.Bio, China);
TBS-Tween20 was used in all dilutions and intervening rinses.
The ections were allowed to develop in diaminobenzidine
(DAB) for 5 min, and then were counterstained with
hematoxylin. The slides were viewed under a microscope. The
sections incubated without primary antibody were
negative controls included in each run.Immunohistochemical staining evaluation
The assessment of DEC1, HIF-1α was as previously
described [9,10], by percentage of stained tumor cells
and staining intensity. We examined a minimum of 3
different high-power (× 400) fields of tumor infiltration.
The percentage of positive tumor cells was rated as follows:
0, staining in ≤10% of tumor cells; 1+, weak staining in
>10% of cells; 2+, moderate staining in >10% of cells; 3+,
strong moderate staining in >10% of cells. Tumors scored
as 3+/2+ were positive cases; tumors scored as 0/1+ were
designated as negative cases. The Ki67 scoring system was
0 assigned for no cells staining positively; 1 for ≤ 10% of
cells staining positively; 2 for > 10% of cells staining
positively. The tumors scored as 3+/2+ were positive
cases; the tumors scored as 0/1+ were designated as
negative cases. Expression was analyzed by 2 independent
investigators who used a multiheaded microscope and
were blinded to the clinical data with consensus.Statistical analysis
The statistical analysis used SPSS v11.5 (SPSS Inc.,
Chicago, IL). A chi-square test was used to test the
association of DEC1 and HIF-1α expression and the
clinicopathological variables. The spearman correlation
analysis was used to assess the correlation between
DEC1 expression and HIF-1α and Ki67 expression.
P < 0.05 was considered statistically significant.
Table 1 Expression of differentiated embryo chondrocyte 1 and hypoxia-inducible factor 1α protein in gastric cancer
and adjacent non-tumor tissues n (%)
Cases DEC1 protein HIF-1α protein
Positive P value Positive P value
Gastric cancer 173 145(83.8%) 0.000 94(54.3%) 0.000
Adjacent non-tumor tissues 173 41(23.7%) 22(12.7%)
DEC1 Differentiated embryo chondrocyte 1, HIF-1a Hypoxia-inducible factor-1.
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Expression of DEC1 and HIF-1α in gastric cancer and
adjacent non-tumour tissues
DEC1 protein expression was located in the nucleus and
cytoplasm of gastric cancer cells and was diffuse in 145 of
173 specimens (83.8%; Table 1, Figure 1A and B). Compared
with the gastric cancer tissue, the adjacent non-tumourFigure 1 Expression of differentiated embryonic chondrocyte-express
protein in human gastric cancer tissue. Brown shows positive expressio
staining for DEC1 (A: SP, × 100; B: SP, × 400). Poorly differentiated gastric c
Poorly differentiated gastric cancer with nuclear staining for Ki67 (E: SP, × 1tissues showed reduced DEC1 expression (23.7%, P <0.001),
with only cytoplasmic positive staining. The proportion of
positive DEC1 nuclear and/or cytoplasmic staining in well
and moderately differentiated tissues was 67.9% (36/53) and
in poorly differentiated tissues 90.8% (109/120), with a sig-
nificant difference found between the two. The total DEC1
protein staining was associated with poorly differentiateded gene 1 (DEC1), hypoxia-inducible factor 1α (HIF-1α) and Ki67
n. Poorly differentiated gastric cancer with nuclear and cytoplasmic
ancer with nuclear staining for HIF-1α (C: SP, × 100; D: SP, × 400).
00; F: SP, × 400).
Table 2 Correlation between the expression of DEC1 and clinicopathological factors
Clinicopathologic
features
DEC1 protein expression P value HIF-1α protein expression P value
Negative Positive Negative Positive
Age (yr) 0.108 0.463
≤50 8 23 16 15
>50 20 122 63 79
Sex 0.082 0.136
Male 15 102 58 59
Female 13 43 21 35
Tumor size (cm) 0.283 0.920
≤5 cm 8 57 30 35
>5 cm 20 88 49 59
Lymph node metastasis 0.082 0.000
Yes 24 101 44 81
No 4 44 35 13
TNM stage 0.397 0.013
I~II 9 59 39 29
III~IV 19 86 40 65
Tumor differentiation status 0.000 0.004
Well and moderate 17 36 33 20
Poor 11 109 46 74
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not differ by tumor size, lymph node metastasis, tumor-
node-metastasis stage, or age or sex of the patients.
Nuclear expression of HIF-1α was found in 54.3% of the
tumors, which was significantly higher than that in the adja-
cent normal tissues (54.3% vs 12.7%, P < 0.01, Table 1,
Figure 1C and D). Furthermore, we also found that the ex-
pression of HIF-1α was correlated with lymph node metas-
tasis, TNM stage and poorly differentiated histological grade
(P < 0.05, Table 2).
Correlation of DEC1 and HIF-1α expression in human
gastric cancer
To study whether DEC1 is associated with HIF-1α in
gastric cancer, we performed a correlative analysis. The
results showed that there is a significant correlation
between nuclear or cytoplasmic DEC1 expression and
nuclear HIF-1α expression (P <0.01, r=0.290; Table 3).Table 3 Correlation between the expression of DEC1 and
HIF-1α
DEC1 expression P value r value
Positive Negative
(n = 145) (n = 28)
HIF-1α expression <0.001 0.290
Positive (n = 94) 88 6
Negative (n = 79) 57 22Correlation of DEC1 and Ki67 expression in human gastric
cancer
In all, 56.9% (98/173) of gastric cancer specimens expressed
Ki67 (Figure 1E and F). DEC1 and Ki67 levels were signifi-
cantly correlated (P <0.01, r = 0.249; Table 4).
Discussion and conclusions
Previous reports of the implications of DEC1 over-
expression in cancer have been inconsistent [10-12], so we
investigated gastric cancer specimens from a large con-
secutive series of gastric cancer patients who had under-
gone similar surgeries. We extended previous studies by
finding a positive correlation between DEC1 and HIF-1α
expression and cancer proliferation.
We found that the DEC1 protein was persistently
expressed in both the cytoplasm and the nucleus of
gastric cancer. DEC1 was also widely expressed in the
cytoplasm of other human tumours, including breastTable 4 Correlation between the expression of DEC1 and
Ki67
DEC1 expression P value r value
Positive Negative
(n = 145) (n = 28)
Ki67 expression 0.001 0.249
Positive (n = 98) 90 8
Negative (n = 75) 55 20
Figure 2 Schematic representation of promotion function of
DEC1 in cell proliferation. DEC1 is inducible by HIF-1α in cancer
cell. The mechanism of this interaction has been shown to be the
HIF-1α/β complex directly binding to the HIF-1 binding site in the
hypoxia response element(HRE) of the DEC1 promoter to initiate the
transcription of DEC1.The cells that lack the functional tumor
suppressor von Hippel-Lindau(VHL) express higher levels of DEC1.
DEC1 is a downstream target of transforming growth factor β
signaling, which promotes the survival of cells. DEC1 transcriptionally
upregulates the expression of the survivin and signal transducer and
activator of transcription 3 (STAT3). Forced expression of DEC1
selectively inhibits the activation of procaspases.
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omas [1]. Only nuclear DEC1 reactivity was found in
some clinicopathological studies [1,13]. These differences
might be explained by the status of the paraffinized
sections, subjective interpretation by pathologists, the
production of antibodies or the variation in techniques.
Although a transcription factor, nuclear DEC1 is likely
to be an active form, which is synthesized and degraded
in the cytoplasm. Its expression may be redistributed
during tissue collection, which would be difficult to
control, but the overall expression indicates upregulation
of the pathway in gastric cancer. In this study, positive
DEC1 staining was found in 145 of 173 (83.8%) specimens,
and nuclear/cytoplasmic DEC1 expression was found to
be significantly correlated with nuclear HIF-1α expression.
The analysis based on pure nuclear expression showed
very marginal or no statistical association with HIF-1α,
showing that strong cytoplasmic DEC1 expression, which
is a tumourspecific finding, better reflects the DEC1
regulated pathway in paraffin-embedded material.
HIF-1α is a well-established molecule induced under
hypoxic conditions [14]. As well, DEC1 is inducible by
HIF-1α in various cancer cell lines [5,15-25]. The mech-
anism of this interaction has been shown to be the
HIF-1α/β complex directly binding to the HIF-1 bind-
ing site in the hypoxia response element of the DEC1
promoter, which initiates the transcription of DEC1
[3,17,26]. Clinical studies revealed a possible association
of HIF-1α and DEC1 expression by immunohistochemical
staining in solid cancers such as non-small lung cancer
and breast cancer [1,2]. HIF-1-dependent hypoxia-induced
DEC1 expression may be in a hypoxic status in solid
cancers. Some studies have shown that the promotion or
inhibition of cell differentiation by DEC1 is cell-type
specific and differs in different original tissues. Over-
expression of Stra13 inhibits mesodermal differentiation
but promotes neuronal differentiation in P19 cells [27].
DEC1 was found to be associated with the hypoxic
response and high tumour grade in human breast cancers
[13]. In hepatocellular carcinoma, the expression of
nuclear DEC1 was greater in well differentiated than
in poorly differentiated malignant hepatocellular car-
cinoma [15]. Furthermore, a positive association between
tumour grade and HIF-1α has been reported [28]. These
observations suggest that tumor hypoxia can inhibit
cancer cell differentiation, and DEC1, induced by
HIF-1α, may function as a HIF-1α effector to mediate
the effect of hypoxia on cell differentiation. Thus,
DEC1 and HIF-1α expression is correlated with poor
differentiation, as we describe, and is in accordance
with the induction by HIF-1α and the ability of DEC1
to repress tumor differentiation.
Dysregulation of cellular proliferation is a prominent
feature of cancers. Ki67 nuclear antigen is a proliferativemarker and is a good indicator of the proliferative and
differentiation ability of gastric carcinoma cells [29].
DEC1 upregulation encourages the growth of malignant
cells by increasing cell proliferation (Figure 2). Cells that
lack the functional tumor suppressor von Hippel-Lindau
express higher levels of DEC1 [26]. DEC1 is a down-
stream target of transforming growth factor β signaling
[17], which promotes the survival of breast cancer
cells. Forced expression of DEC1 antagonizes serum
deprivation-induced apoptosis and selectively inhibits
the activation of procaspases [5]. DEC1 transcription-
ally upregulates the expression of the survivin [6] and
signal transducer and activator of transcription 3 [30],
providing a molecular explanation for DEC1 anti-
apoptosis. In contrast, DEC1 induces apoptosis in mouse
fibroblast NIH3T3 cells, possibly through the regulation
of p53 [7]. DEC1 may play a key role in signaling
pathways that lead to growth arrest and terminal differ-
entiation by repressing target genes via histone deacetylase-
dependent and -independent mechanisms [31]. DEC1
overexpression induces the apoptosis of breast cancer
MCF-7 cells [8]. DEC1 also acts as a transcriptional re-
pressor to inhibit the transcription of cyclin D1, which
is associated with cell proliferation and tumorigenesis
[32]. The promotion or inhibition function of DEC1 in
cell proliferation may depend on the cell type. In our
study, DEC1 positively correlated with the cell proliferation
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and Ki67 in poorly differentiated tissues implied that the
tumor cells lost growth control in gastric carcinogenesis,
thus leading to a DNA synthesis disorder, which reflected
the malignant behavior of tumor cells.
In this study, we did not find any association between
lymph node metastasis, TNM stage and DEC1 expression,
which was in agreement with a study by Chakrabarti
J et al. [13] study. Nevertheless, upregulation of DEC1
is strongly associated with HIF-1a and Ki67,previously
shown to be associated with aggressive clinical behavior
[9,28,33,34], which supports that DEC1 is a marker of
activated hypoxic pathways and a novel biomarker of
clinical aggressiveness. Although further investigations
are needed to clarify the molecular mechanisms involved
in DEC1 overexpression, DEC1 may be a valuable thera-
peutic target in gastric cancer.
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